Meeting
2014 ASCO Annual Meeting
Pretreatment serum levels of circulating myeloid-derived suppressor cells (MDSC) as a prognostic indicator in patients with gastrointestinal cancer.
Authors
Masahiko Shibata
Saitama Medical University, Saitama, Japan
Masahiko Shibata , Kenji Gonda , Takahiro Nakajima , Yoshiko Matsumoto , Izumi Nakamura , Shinji Ohki , Tohru Ohtake , Kensuke Kumamoto , Tatsuo Shimura , Seiichi Takenoshita , Noriko Abe , Tomoyuki Momma
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Immunotherapy
Track
Developmental Therapeutics
Sub Track
Immunotherapy and Biologic Therapy
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 3059)
DOI
10.1200/jco.2014.32.15_suppl.3059
Abstract #
3059
Poster Bd #
126
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
Blood myeloid derived suppressor cells (MDSC) in metastatic urothelial carcinoma (mUC) are correlated with neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS).
First Author: Iris Yeong- Fung Sheng
Poster
2018 Gastrointestinal Cancers Symposium
Correlation of VEGF with immune suppression involving MDSC, malnutrition, and prognosis in patients with gastric and colorectal cancer.
First Author: Kenji Gonda
Poster
2012 Gastrointestinal Cancers Symposium
Relationship of myeloid-derived suppressor cells (MDSC) and immune suppression, nutritional impairment, and inflammatory markers in patients with gastrointestinal cancer.
First Author: Masahiko Shibata
Poster
2024 ASCO Breakthrough
The dynamic changes of circulating myeloid-derived suppressor cells (MDSCs) subsets in patients with colorectal cancer undergoing oxaliplatin-based chemotherapy.
First Author: Dilafitria Fauza